Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Tse, Gary; Ip, Christina; Luk, King Sum; Gong, Mengqi; Ting, Yuen Ha; Lakhani, Ishan; Bazoukis, George; Li, Guangping; Letsas, Κonstantinos P.; Dong, Mei; Liu, Tong; Wong, Martin C. S.

doi:10.1136/heartasia-2017-010980

Cited by 10 publications

(7 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NT‐proBNP has an established role in the prognosis and diagnosis of heart failure, and prior studies evaluating patients with AS have found that natriuretic peptides positively correlate with progressive AS severity and worse outcomes, including higher mortality, increased heart failure hospitalization, and symptoms following AVR 8,16,22,23 . ST2, a marker of inflammation and fibrosis, has been shown to be associated with heart failure symptoms and prognosis following AVR, 7,24 and demonstrated a strong association with death and DHFA in our analysis. However, in contrast with prior studies, while troponin (cardiomyocyte injury) and GDF‐15 (inflammation/fibrosis) were significantly associated with death/DHFA in unadjusted analyses in our study, they did not meet significance at the Bonferroni‐corrected level in our multivariate analyses.…”

Section: Discussionsupporting

confidence: 58%

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis

Vidula

Orlenko

Zhao

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 58%

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis

Vidula

Orlenko

Zhao

et al. 2021

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…Based on the above principles, sST2 has been widely investigated on its potential to become a prognostic biomarker for pulmonary hypertension [8] , post-aortic valve replacement [9] and cardiovascular diseases (CVDs) [10] . Although some studies reported its predictive value for risk stratification in the context of CVDs, data on its value in predicting disease severity or mortality outcomes are inconclusive.…”

Section: Introductionmentioning

confidence: 99%

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis

Ip¹,

Luk²,

Yuen³

et al. 2021

IJC Heart & Vasculature

Self Cite

View full text Add to dashboard Cite

Objectives Soluble suppression of tumorigenicity 2 (sST2) is a member of the interleukin-1 receptor family. It is raised in various cardiovascular diseases, but its value in predicting disease severity or mortality outcomes has been controversial. Therefore, we conducted a systematic review and meta -analysis to determine whether sST2 levels differed between survivors and non-survivors of patients with cardiovascular diseases, and whether elevated sST2 levels correlated with adverse outcomes. Methods PubMed and Embase were searched until 23rd June 2021 for studies that evaluated the relationship between sST2 levels and cardiovascular disease severity or mortality. Results A total of 707 entries were retrieved from both databases, of which 14 studies were included in the final meta -analysis. In acute heart failure, sST2 levels did not differ between survivors and non-survivors (mean difference [MD]: 24.2 ± 13.0 ng/ml; P = 0.06; I 2 : 95%). Elevated sST2 levels tend to be associated with increased mortality risk (hazard ratio [HR]: 1.12, 95 %CI: 0.99–1.27, P = 0.07; I 2 : 88%). In chronic heart failure , sST2 levels were higher in non-survivors than in survivors (MD: 0.19 ± 0.04 ng/ml; P = 0.001; I 2 : 0%) and elevated levels were associated with increased mortality risk (HR: 1.64, 95% CI: 1.27–2.12, P < 0.001; I 2 : 82%). sST2 levels were significantly higher in severe disease compared to less severe disease (MD: 1.56 ± 0.46 ng/ml; P = 0.001; I 2 : 98%). Finally, in stable coronary artery disease, sST2 levels were higher in non-survivors than survivors (MD: 3.0 ± 1.1 ng/ml; P = 0.005; I 2 : 80%) and elevated levels were significantly associated with increased mortality risk (HR: 1.32, 95% CI: 1.04–1.68, P < 0.05; I 2 : 57%). Conclusions sST2 significantly predicts disease severity and mortality in cardiovascular disease and is a good predictor of mortality in patients with stable coronary artery disease and chronic heart failure.

show abstract

“…Soluble ST2 is an FDA approved biomarker to evaluate prognosis of mortality in chronic heart failure. Previous meta-analyses of sST2 have also been performed in CAD and post-aortic valve replacement patients [ 14 , 16 , 18 , 19 ] and showed that higher sST2 levels were associated with poor clinical outcomes in these populations. The current meta-analysis shows sST2 is associated with risk of poor outcomes of mortality, MACE and adverse cardiovascular events in a wide definition of CVD patients as well as community populations without identified cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Interleukin (IL)-33 and its unique receptor, ST2, play a pivotal role in the immune response to infection and stress. However, there have been conflicting reports of the role of IL-33 in cardiovascular disease (CVD) and the potential of this axis in differentiating CVD patients and controls and with CVD disease severity, remains unclear. Aims 1) To quantify differences in circulating IL-33 and/or sST2 levels between CVD patients versus controls. 2) Determine association of these biomarkers with mortality in CVD and community cohorts. Methods and results Using Pubmed/MEDLINE, Web of Science, Prospero and Cochrane databases, systematic review of studies published on IL-33 and/or sST2 levels in patients with CVD (heart failure, acute coronary syndrome, atrial fibrillation, stroke, coronary artery disease and hypertension) vs controls, and in cohorts of each CVD subtype was performed. Pooled standardised mean difference (SMD) of biomarker levels between CVD-cases versus controls and hazard ratios (HRs) for risk of mortality during follow-up in CVD patients, were assessed by random effects meta-analyses. Heterogeneity was evaluated with random-effects meta-regressions. From 1071 studies screened, 77 were meta-analysed. IL-33 levels were lower in HF and CAD patients vs controls, however levels were higher in stroke patients compared controls [Meta-SMD 1.455, 95% CI 0.372–2.537; p = 0.008, I2 = 97.645]. Soluble ST2 had a stronger association with risk of all-cause mortality in ACS (Meta-multivariate HR 2.207, 95% CI 1.160–4.198; p = 0.016, I2 = 95.661) than risk of all-cause mortality in HF (Meta-multivariate HR 1.425, 95% CI 1.268–1.601; p<0.0001, I2 = 92.276). There were insufficient data to examine the association of IL-33 with clinical outcomes in CVD. Conclusions IL-33 and sST2 levels differ between CVD patients and controls. Higher levels of sST2 are associated with increased mortality in individuals with CVD. Further study of IL-33/ST2 in cardiovascular studies is essential to progress diagnostic and therapeutic advances related to IL-33/ST2 signalling.

show abstract

Prognostic value of soluble ST2 postaortic valve replacement: a meta-analysis

Abstract: sST2 significantly predicts all-cause mortality in patients who have undergone AVR, but this conclusion is limited by the small number of patients. Larger prospective studies are required to better elucidate its value for risk stratification in this patient population.

Cited by 10 publications

References 23 publications

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis

Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis

Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and meta-analysis

Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis

Contact Info

Product

Resources

About